Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of hAd5-S-Fusion+N-ETSD Vaccine in Healthy Adults
NCT04732468Phase 1Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of hAd5-S-Fusion + N-ETSD in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by ImmunityBio, Inc. Primary endpoints: Incidence of Solicited Local Reactogenicity Adverse Events at 1 week, Incidence of Solicited Systemic Treatment-Related Reactogenicity Adverse Events at 1 week and 4 more. Started Feb 2021; status: terminated.
02
Drugs
hAd5-S-Fusion + N-ETSD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04732468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732468.